<DOC>
	<DOCNO>NCT01184105</DOCNO>
	<brief_summary>A phase I , single-center , double-blind , randomize , placebo-controlled , safety pharmacokinetic study evaluate systemic local vaginal exposure lidocaine prilocaine metabolite , 2,6-dimethylaniline ( 2,6-DMA ) o-toluidine , female healthy volunteer subject follow daily application 60 mg PSD502 placebo vagina cervix seven day</brief_summary>
	<brief_title>A Safety Tolerability PSD502 ( Topical Anesthetic ) Treatment Premature Ejaculation</brief_title>
	<detailed_description>The study drug metered-dose anesthetic spray , develop treatment premature ejaculation ( PE ) . The use anesthetic topical cream well establish . The use cream result concentrate drug direct contact cell , unlike spray . Seven clinical study already carry spray development PE . These study demonstrate prolongation intravaginal ejaculatory latency time safety concern male patient female partner . The partner clinical study participant ask report health change study . Reports vaginal numbness uncommon ; however , effect transfer partner exclude . This study conduct investigate detail systemic exposure PSD502 spray order ass safety female partner . The dose level choose total dose apply male glans penis 30 mg , thus potentially possible partner could expose dose . Therefore , 60 mg dose choose provide safety information high margin exposure .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Premature Ejaculation</mesh_term>
	<mesh_term>EMLA</mesh_term>
	<criteria>Female nonsmoker age 18 year old Willing able provide write informed consent Generally , good health opinion investigator Subject must body mass index 18 30 kg/m2 , inclusive Willing able comply study procedure opinion investigator Negative Papanicolaou ( Pap ) smear perform gynecological examination screening ( i.e. , Pap smear result read negative intraepithelial lesion reparative reactive change sign presence infection [ e.g. , bacterial vaginosis , candida , bacterial flora , etc ] ) Negative drug abuse cotinine test screen Female subject childbearing potential sexually active become sexually active must use method effective contraception 14 day screen continue use end study . If oral contraceptive use , must stable period 3 month . If barrier method use , latex base polyurethane base Female subject postmenopausal must postmenopausal &gt; 1 year confirm elevate serum follicle stimulate hormone screen History significant medical condition would preclude study participation opinion investigator Currently take , take within 2 week prior screen , concomitant medication could confound interpretation safety pharmacokinetic data PSD502 . Use prescription medication within 14 day overthecounter product within 7 day prior first dose Suffering sexually transmit disease , positive hepatitis B , hepatitis C , human papillomavirus , human immunodeficiency virus infection Safety testing : abnormality screen , particular liver function test , indicative medical condition would preclude participation opinion investigator Significant abnormality vaginal mucosa cervix would preclude interpretation examination area could worsen use PSD502 History alcohol drug abuse within 1 year prior screen Known drug sensitivity amidetype local anesthetic Unlikely understand able comply study procedure , reason , opinion investigator History glucose6phosphate dehydrogenase deficiency use medication would increase susceptibility methemoglobinemia ( e.g. , antimalarial agent ) Use class I ( e.g. , mexiletine , tocainide ) III ( e.g. , amiodarone , sotalol ) antiarrhythmic drug Subject receive investigational ( nonregistered ) drug within 60 day screen Subjects physical psychological condition would prevent undertake study procedure , include limited , follow : Urogynecological disease recent genitourinary surgery within 8 week screen would make intravaginal application vaginal examination/colposcopy difficult painful Ongoing significant psychiatric disorder ( e.g. , bipolar disease , depression/anxiety disorder schizophrenia ) Subject clinically obvious vaginal infection , active vaginal Candida albicans ( thrush ) , abnormal vaginal discharge Subjects pregnant lactating Subjects menstruate treatment phase Donation blood blood product within 60 day prior dose time study , except require protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>